Published in J Virol on April 01, 1995
Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol (1996) 4.45
Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol (1996) 3.39
Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol (1999) 3.32
Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol (1997) 3.29
Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol (1998) 2.92
Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother (1998) 2.67
Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug. J Virol (2000) 2.27
In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects. J Virol (1996) 2.22
Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother (1996) 2.13
In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J Virol (1998) 2.13
Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. Proc Natl Acad Sci U S A (1996) 1.93
In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob Agents Chemother (2000) 1.59
Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother (1997) 1.53
Deoxyribonucleoside triphosphate pool imbalances in vivo are associated with an increased retroviral mutation rate. J Virol (1998) 1.40
Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy. J Virol (1998) 1.38
Human immunodeficiency virus type 1 cloning vectors for antiretroviral resistance testing. J Clin Microbiol (1999) 1.28
Protease inhibitors as antiviral agents. Clin Microbiol Rev (1998) 1.25
The antiretrovirus drug 3'-azido-3'-deoxythymidine increases the retrovirus mutation rate. J Virol (1997) 1.16
Viral evolution in response to the broad-based retroviral protease inhibitor TL-3. J Virol (2001) 1.03
Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors. J Virol (1999) 0.95
Emergence of protease inhibitor resistance mutations in human immunodeficiency virus type 1 isolates from patients and rapid screening procedure for their detection. Antimicrob Agents Chemother (1996) 0.93
Toward a universal inhibitor of retroviral proteases: comparative analysis of the interactions of LP-130 complexed with proteases from HIV-1, FIV, and EIAV. Protein Sci (1998) 0.90
Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain. J Virol (2000) 0.88
Characterization of siamycin I, a human immunodeficiency virus fusion inhibitor. Antimicrob Agents Chemother (1996) 0.86
Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis. Microbiol Mol Biol Rev (2000) 0.78
Evaluation of PD 404,182 as an anti-HIV and anti-herpes simplex virus microbicide. Antimicrob Agents Chemother (2013) 0.75
Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science (1988) 220.77
Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci U S A (1985) 68.48
DNA sequence analysis with a modified bacteriophage T7 DNA polymerase. Proc Natl Acad Sci U S A (1987) 37.15
Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science (1989) 15.19
Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science (1991) 8.76
Complete mutagenesis of the HIV-1 protease. Nature (1989) 5.16
Rational design of peptide-based HIV proteinase inhibitors. Science (1990) 4.57
New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J Natl Cancer Inst (1989) 4.04
Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine. J Virol (1992) 3.46
Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J Virol (1994) 3.45
Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science (1994) 3.44
Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture. J Virol (1991) 3.33
L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci U S A (1994) 3.00
The HIV-1 protease as a therapeutic target for AIDS. AIDS Res Hum Retroviruses (1992) 2.69
Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother (1993) 2.68
Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc Natl Acad Sci U S A (1994) 2.59
In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease. Proc Natl Acad Sci U S A (1993) 2.16
HIV protease: a novel chemotherapeutic target for AIDS. J Med Chem (1991) 1.90
Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor. J Virol (1994) 1.80
Autoprocessing of the HIV-1 protease using purified wild-type and mutated fusion proteins expressed at high levels in Escherichia coli. Eur J Biochem (1991) 1.29
Discovery of a novel class of potent HIV-1 protease inhibitors containing the (R)-(hydroxyethyl)urea isostere. J Med Chem (1993) 1.23
PCR amplification of HIV-1 proteinase sequences directly from lab isolates allows determination of five conserved domains. Virology (1992) 1.13
In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations. Antimicrob Agents Chemother (1992) 1.13
Symmetry-based inhibitors of HIV protease. Structure-activity studies of acylated 2,4-diamino-1,5-diphenyl-3-hydroxypentane and 2,5-diamino-1,6-diphenylhexane-3,4-diol. J Med Chem (1993) 1.07
Affinity purification of the HIV-1 protease. Biochem Biophys Res Commun (1989) 1.05
In vitro anti-human immunodeficiency virus (HIV) activity of XM323, a novel HIV protease inhibitor. Antimicrob Agents Chemother (1993) 1.00
Antiviral properties of aminodiol inhibitors against human immunodeficiency virus and protease. Antimicrob Agents Chemother (1995) 0.98
Aminodiol HIV protease inhibitors. 1. Design, synthesis, and preliminary SAR. J Med Chem (1994) 0.91
A unique RNA species involved in initiation of vesicular stomatitis virus RNA transcription in vitro. Cell (1976) 3.82
Use of monoclonal antibodies to identify four neutralization immunogens on a common cold picornavirus, human rhinovirus 14. J Virol (1986) 3.59
Many rhinovirus serotypes share the same cellular receptor. J Virol (1984) 3.59
Vesicular stomatitis virus: mode of transcription. J Gen Virol (1977) 3.53
In vitro synthesis of an infectious RNA from cDNA clones of human rhinovirus type 14. J Virol (1985) 3.19
Patterns of smoking in Russia. Tob Control (1998) 3.17
Molecular cloning and complete sequence determination of RNA genome of human rhinovirus type 14. Proc Natl Acad Sci U S A (1985) 3.17
cDNA cloning reveals that the major group rhinovirus receptor on HeLa cells is intercellular adhesion molecule 1. Proc Natl Acad Sci U S A (1989) 3.09
Complete nucleotide sequence of the leader RNA synthesized in vitro by vesicular stomatitis virus. Cell (1978) 3.06
Assessing the impact of Cry1Ab-expressing corn pollen on monarch butterfly larvae in field studies. Proc Natl Acad Sci U S A (2001) 2.78
Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother (2004) 2.67
De novo initiation of RNA synthesis by the RNA-dependent RNA polymerase (NS5B) of hepatitis C virus. J Virol (2000) 2.65
Helicobacter mustelae-associated gastritis in ferrets. An animal model of Helicobacter pylori gastritis in humans. Gastroenterology (1990) 2.64
The protease of herpes simplex virus type 1 is essential for functional capsid formation and viral growth. J Virol (1994) 2.61
Socioeconomic factors, material inequalities, and perceived control in self-rated health: cross-sectional data from seven post-communist countries. Soc Sci Med (2000) 2.57
Isolation of a monoclonal antibody that blocks attachment of the major group of human rhinoviruses. J Virol (1986) 2.54
The major and minor group receptor families contain all but one human rhinovirus serotype. Virology (1991) 2.50
Alcohol consumption in a national sample of the Russian population. Addiction (1999) 2.33
Molecular cloning and structural analysis of murine thymidine kinase genomic and cDNA sequences. Mol Cell Biol (1985) 2.13
A collaborative report: rhinoviruses--extension of the numbering system from 89 to 100. Virology (1987) 2.10
Socioeconomic factors, perceived control and self-reported health in Russia. A cross-sectional survey. Soc Sci Med (1998) 2.09
Epidemiology of smoking in Ukraine, 2000. Prev Med (2001) 2.05
Substrate requirements of human rhinovirus 3C protease for peptide cleavage in vitro. J Biol Chem (1990) 1.99
Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother (1997) 1.94
Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. Proc Natl Acad Sci U S A (1996) 1.93
Identification of the herpes simplex virus-1 protease cleavage sites by direct sequence analysis of autoproteolytic cleavage products. J Biol Chem (1993) 1.92
Intervening polyadenylate sequences in RNA transcripts of vesicular stomatitis virus. Cell (1978) 1.92
Prevalence and determinants of smoking in Belarus: a national household survey, 2000. Eur J Epidemiol (2001) 1.89
Interferon induction of fibroblast proteins with guanylate binding activity. J Biol Chem (1983) 1.87
Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest (1995) 1.78
Mapping and initiation studies on the leader RNA of vesicular stomatitis virus. Virology (1977) 1.78
Induction of unique mRNAs by human interferons. J Biol Chem (1982) 1.76
Isolation of a receptor protein involved in attachment of human rhinoviruses. J Virol (1986) 1.68
Monoclonal antibody that inhibits infection of HeLa and rhabdomyosarcoma cells by selected enteroviruses through receptor blockade. J Virol (1986) 1.68
Cloning and expression of murine lymphotoxin cDNA. J Immunol (1987) 1.62
In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob Agents Chemother (2000) 1.59
In vitro synthesis of messenger RNA by a defective interfering particle of vesicular stomatitis virus. Proc Natl Acad Sci U S A (1977) 1.51
Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection. Antimicrob Agents Chemother (1998) 1.45
Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother (2002) 1.45
Eosinophilic gastroenteritis with Splendore-Hoeppli material in the ferret (Mustela putorius furo). Vet Pathol (1992) 1.42
Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors. Antimicrob Agents Chemother (1992) 1.39
Induction of tumor necrosis factor, IFN-gamma, and acute lethality in mice by toxic and non-toxic forms of lipid A. J Immunol (1988) 1.38
Cleavage of small peptides in vitro by human rhinovirus 14 3C protease expressed in Escherichia coli. J Virol (1989) 1.38
NHS laboratories can provide a service to the pharmaceutical industry: a personal experience. Ann Clin Biochem (2000) 1.38
Asteroid 1950 DA's encounter with Earth in 2880: physical limits of collision probability prediction. Science (2002) 1.38
In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother (1998) 1.36
Human-murine chimeras of ICAM-1 identify amino acid residues critical for rhinovirus and antibody binding. J Virol (1991) 1.36
Cell surface receptors for picornaviruses. Bioessays (1986) 1.35
The value of constant surveillance in a risky environment. Proc Biol Sci (2009) 1.35
Initiation of genetic exchanges in lambda phage--prophage crosses. Proc Natl Acad Sci U S A (1977) 1.34
Changes in smoking prevalence in Russia, 1996-2004. Tob Control (2006) 1.32
Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob Agents Chemother (1999) 1.27
Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J Infect Dis (1994) 1.27
Biochemical studies on capped RNA primers identify a class of oligonucleotide inhibitors of the influenza virus RNA polymerase. Proc Natl Acad Sci U S A (1994) 1.27
Use of polymorphic short and clustered coding-region microsatellites to distinguish strains of Candida albicans. FEMS Immunol Med Microbiol (1996) 1.27
Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther (2001) 1.26
BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob Agents Chemother (2000) 1.26
Distribution of persistent Salmonella typhimurium infection in internal organs of swine. Am J Vet Res (1989) 1.25
Dietary poorly absorbed, short-chain carbohydrates increase delivery of water and fermentable substrates to the proximal colon. Aliment Pharmacol Ther (2010) 1.24
Blizzard morbidity and mortality: Rhode Island, 1978. Am J Public Health (1979) 1.24
Methylation of messenger RNA of Newcastle disease virus in vitro by a virion-associated enzyme. Proc Natl Acad Sci U S A (1975) 1.24
Genetic exchanges caused by ultraviolet photoproducts in phage lambda DNA molecules: the role of DNA replication. Mol Gen Genet (1976) 1.24
The role of the left prefrontal cortex in verbal processing: semantic processing or willed action? Neuroreport (1994) 1.23
Populations of Salmonella typhimurium in internal organs of experimentally infected carrier swine. Am J Vet Res (1992) 1.22
Antigenic conservation and divergence between the viral-specific proteins of poliovirus type 1 and various picornaviruses. Virology (1985) 1.20
Partial purification and characterization of the mRNA for human thymidine kinase and hypoxanthine/guanine phosphoribosyltransferase. Proc Natl Acad Sci U S A (1982) 1.19
Nucleotide sequence of the leader RNA of the New Jersey serotype of vesicular stomatitis virus. Nucleic Acids Res (1978) 1.18
Identification of the serine residue at the active site of the herpes simplex virus type 1 protease. J Biol Chem (1994) 1.17
Antibodies that block rhinovirus attachment map to domain 1 of the major group receptor. J Virol (1990) 1.17
Genomic cloning and preliminary characterization of the human thymidine kinase gene. Proc Natl Acad Sci U S A (1983) 1.16
Chimeric picornavirus polyproteins demonstrate a common 3C proteinase substrate specificity. J Virol (1989) 1.15
Isolation of a transcriptive complex from Newcastle disease virions. J Virol (1976) 1.15
The importance of the relationship between scale and process in understanding long-term DOC dynamics. Sci Total Environ (2010) 1.15
Characterization of vesicular stomatitis virus mRNA species synthesized in vitro. J Virol (1977) 1.14
BMS-182123, a fungal metabolite that inhibits the production of TNF-alpha by macrophages and monocytes. J Antibiot (Tokyo) (1996) 1.13
Protection of mice against Listeria monocytogenes infection by recombinant human tumor necrosis factor alpha. Infect Immun (1989) 1.12
Accumulation of newly synthesized mRNAs in response to human fibroblast (beta) interferon. Proc Natl Acad Sci U S A (1981) 1.10
Newcastle disease virus mRNA lacks 2'-O-methylated nucleotides. Nature (1976) 1.10
Transcriptional and posttranscriptional mechanisms regulate murine thymidine kinase gene expression in serum-stimulated cells. Mol Cell Biol (1988) 1.09
Interaction of a limited set of proteins with different mRNAs and protection of 5'-caps against pyrophosphatase digestion in initiation complexes. Nucleic Acids Res (1979) 1.07
Prospective identification of biologically active structures by topomer shape similarity searching. J Med Chem (1999) 1.06
Biochemical characterization of a glycoprotein required for rhinovirus attachment. J Biol Chem (1989) 1.05
Analysis of compartmentation of ATP in skeletal and cardiac muscle using 31P nuclear magnetic resonance saturation transfer. Biophys J (1987) 1.05
Age-related prevalence, intensity and frequency distribution of gastrointestinal helminth infection in urban slum children from Kuala Lumpur, Malaysia. Trans R Soc Trop Med Hyg (1988) 1.04
Characterization of human rhinoviruses displaced by an anti-receptor monoclonal antibody. J Virol (1988) 1.04
Stavudine resistance: an update on susceptibility following prolonged therapy. Antivir Ther (1999) 1.04
Toxicity--seizures in an infant caused by (or related to) oral viscous lidocaine use. J Emerg Med (1992) 1.04
Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication. Antimicrob Agents Chemother (1996) 1.03
A hyaluronate based gel for the prevention of postsurgical adhesions: evaluation in two animal species. Fertil Steril (1996) 1.02
Quantification of fructans, galacto-oligosacharides and other short-chain carbohydrates in processed grains and cereals. J Hum Nutr Diet (2011) 1.02
Photoengraving of coverslips and slides to facilitate monitoring of micromanipulated cells or chromosome spreads. Exp Cell Res (1981) 1.01